Krystal Brown, PhD

The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis

Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...

Ken Yu , MS;

Holly Johnson , PhD;

Krystal Brown , PhD;

Michael Jablonski , PhD;

Bryan Dechairo , PhD;

Lisa Brown , PhD;

Oliver Vranjkovic , PhD;

James Li , MS, PhD;

10/08/2020

Combinatorial Pharmacogenomic Testing Improves Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized, Controlled Trial

Objectives: The GUIDED trial demonstrated that combinatorial pharmacogenomic (PGx) testing significantly improved the rate of response (p=0.007) and remission (p=0.005) and approached sig...

John Greden , MD;

Anthony Rothschild , MD;

Michael Thase , MD;

Boadie Dunlop , MD;

Richard Shelton , MD;

Charles Conway , MD;

Lisa Brown , PhD;

Jennie Depatie , PhD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Matthew Macaluso , DO;

Krystal Brown , PhD;

Michael J. Crescenz ;

Michael Jablonski , PhD;

Charles DeBattista , MD;

Sagar Parikh , MD;

11/22/2019

Using a Genetic Test (Combinatorial Pharmacogenomics)To Help Choose Patient-Specific Antidepressants for Depression: a Large, Blinded, Randomized Control Trial

Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...

Anthony Rothschild , MD;

Boadie Dunlop , MD;

Michael Thase , MD;

Charles Conway , MD;

Richard Shelton , MD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Francis Mondimore , MD;

Krystal Brown , PhD;

Matthew Macaluso , DO;

Michael Jablonski , PhD;

Alexa Gilbert , MSc, MBA;